Pharma feed

  • Hoffmann-La Roche Ltd
  • Events
  • Social Updates
  • Twitter
N
UCB SA
Unb (com.bd)· 17 Nov 2019

UCB among top tax payers

United Commercial Bank Limited (UCB) has been honoured as one of the top tax payers in the banking category. Arif Quadri, Additional Managing Director of UCB received the Tax Card and honor crest on behalf of the bank from Finance Minister A H M Mustafa Kamal, and Chairman of National Bureau of Revenue (NBR)Md Mosharraf Hossain Bhuiyan, NDC at a hotel in the capital on Thursday.

  • UCB SA
  • United Commercial Bank
  • Awards and Recognitions
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
San Diego Business Journal· 17 Nov 2019

Merck Agrees to Buy Calporta in Deal That Could Be Worth $576M

In 2017, Merck & Co... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subscriber-only digital content every business day, plus full access to

  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
  • Amgen, Inc.
  • Events
  • Social Updates
  • Twitter
  • Amgen, Inc.
  • Events
  • Social Updates
  • Twitter
  • Regeneron Pharmaceuticals Inc
  • Events
  • Social Updates
  • Twitter
Amgen, Inc.
Amgen· 16 Nov 2019

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

THOUSAND OAKS, Calif.,Nov. 16, 2019/PRNewswire/ --Amgentoday announced a new analysis from the Repatha®(evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who have suffered a recent myocardial infarction (MI). The analysis showed that patients who experienced a recent MI (less than one year) were at higher risk of subsequent cardiovascular (CV) events compared to patients who had an MI over a year ago.

  • Amgen, Inc.
  • Procurement and Sales
  • Press Releases
  • Company Websites
  • C3 Metrics
  • Microsoft Corporation
  • Merck & Co., Inc.
  • Adobe Systems Incorporated
  • Events
  • Social Updates
  • Twitter
N
Johnson & Johnson
Business Standard· 16 Nov 2019

US Judge reduces J&J Opioid fine after mistaking thousands for millions

In a mortifying mistake destined to be cited by gleeful math teachers everywhere, an Oklahoma judge acknowledged that he was three decimal places off — mistaking thousands for millions — when he originally calculated the amount Johnson & Johnson should pay for its role in the state’s opioids crisis.

  • Johnson & Johnson
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Sanofi
Pakistan Company News· 16 Nov 2019

Board Meeting other than Financial Result of Sanofi – Aventis Pakistan Limited – Pakistan Company News

Karachi, Sanofi – Aventis Pakistan Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on November 14, 2019 at Karachi, to discussed and reviewed in detail the long range plan of the Company.

  • Sanofi
  • Financial and Business Performance
  • News Articles
  • Company Websites
N
Pfizer Inc.
The Center for Biosimilars· 16 Nov 2019

FDA Approves Pfizer's Adalimumab Biosimilar, Abrilada

The FDA has approved Pfizer’s adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira.In a statement, Sarah Yim, MD, acting director of the FDA’s Office of Therapeutic Biologics and Biosimilars in the Center for Drug Evaluation and Research,

  • Center for Drug Evaluation and Research
  • Pfizer Inc.
  • Procurement and Sales
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
The Pharma Letter· 16 Nov 2019

BRIEF—Merck Research Labs appointment

Dr Theodora Ross has been appointed vice president of translational medicine for the discovery, pre-clinical and early development at Merck Research Laboratories, a division of Merck & Co. Dr Ross will start her new role in December 2019 and will be based at Merck’s Rahway, New Jersey, site.

  • Merck & Co., Inc.
  • Management Changes
  • News Articles
  • News and Other Websites
N
Celgene Corp
The Economic Times· 16 Nov 2019

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

WASHINGTON: Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.Bristol-Myers Squibb said the decision meant it had all the needed regulatory approvals and would close the acquisition on Wednesday.Amgen has agreed to buy Celgene's Otezla business, the company said in a statement.

  • Celgene Corp
  • Bristol-Myers Squibb Co
  • M&A Activities
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Newkerala.com· 16 Nov 2019

Merck Foundation marks World Diabetes Day 2019 by launching their Nationwide Diabetes Blue Points Project to advance diabetes care in African countries, Business India News:

Mumbai Nov 15: Merck Foundation, the philanthropic arm of Merck KGaA Germany marked 'World Diabetes Day 2019' by building diabetes care capacity in Africa and Asia. "We strongly believe that starting the 'Merck Nationwide Diabetes Blue Points Project' is the right strategy to ensure that every provenance in Africa will have the diabetes care they deserve and not only the capital or main cities.

  • Blue & Co., LLC
  • Merck & Co., Inc.
  • Procurement and Sales
  • New Offerings
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Medical Xpress· 16 Nov 2019

Judge lowers opioid settlement to $465 million, blames error

Johnson & Johnson will now have to pay Oklahoma $465 million after a judge admitted he'd made a mistake in calculating a verdict against the pharmaceutical giant for its role in fueling the opioid crisis An Oklahoma judge who had ordered Johnson & Johnson to pay $572 million for its role in the opioid crisis on Friday reduced the figure to $465 million, after a miscalculation.

  • Johnson & Johnson
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Novartis AG
Novartis· 16 Nov 2019

Analyst, VC Sales Operations

The Commercial Operations Analyst is responsible for assisting the Vision Care sales teams in driving profitable revenue growth and becoming more efficient by:• Responding to the needs of sales leadership by providing timely, accurate data.•

  • Vision Care
  • Novartis AG
  • Financial and Business Performance
  • Company Websites
N
AstraZeneca PLC
Pharmabiz· 16 Nov 2019

AstraZeneca and MSD announces US FDA accepts selumetinib NDA and grants priority review status

AstraZeneca and MSD Inc, announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for selumetinib as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (Pns).

  • AstraZeneca PLC
  • MSD
  • Procurement and Sales
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Court House News· 16 Nov 2019

Oklahoma Judge Lowers Opioid Damages by $107 Million

NORMAN, Okla. (CN) – The Oklahoma judge that awarded the state $572 million from Johnson & Johnson in the first opioid crisis lawsuit to go to trial formally reduced his damages award by $107 million Friday, admitting to a three-digit calculation error.

  • Johnson & Johnson
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Medscape
Medscape News· 16 Nov 2019

FDA OKs Crizanlizumab, Targeted Therapy for Sickle Cell Crisis

The US Food and Drug Administration (FDA) has approved crizanlizumab (Adakveo, Novartis) to reduce the frequency of vaso-occlusive crisis in patients aged 16 years or older with sickle cell disease.

  • Medscape
  • Novartis AG
  • Regulatory and Legal
  • Press Releases
  • News and Other Websites
  • RES Ltd
  • Amgen, Inc.
  • Awards and Recognitions
  • Social Updates
  • Twitter
N
Pfizer Inc.
Seeking Alpha· 16 Nov 2019

FDA OKs Pfizer biosimilar to Humira

The FDA approves Pfizer's (NYSE:PFE) Abrilada (adalimumab-afzb), a biosimilar to AbbVie's (NYSE:ABBV) top seller Humira. Abrilada is the 25th biosimilar approved in the U.S.

  • Pfizer Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Celgene Corp
FirstWord Pharma· 16 Nov 2019

Bristol-Myers Squibb wins US antitrust approval for Celgene acquisition

Bristol-Myers Squibb announced Friday that the US Federal Trade Commission (FTC) has cleared its pending $74-billion Celgene acquisition, adding it now expects the merger to become final on November 20. The FTC decision follows Celgene's recent deal to divest Otezla (apremilast) to Amgen for $13.4 billion.

  • Celgene Corp
  • Bristol-Myers Squibb Co
  • M&A Activities
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Celgene Corp
FirstWord Pharma· 16 Nov 2019

Bristol-Myers Squibb wins US antitrust approval for Celgene acquisition

Bristol-Myers Squibb announced Friday that the US Federal Trade Commission (FTC) has cleared its pending $74-billion Celgene acquisition, adding it now expects the merger to become final on November 20. The FTC decision follows Celgene's recent deal to divest Otezla (apremilast) to Amgen for for $13.4 billion.

  • Celgene Corp
  • Bristol-Myers Squibb Co
  • M&A Activities
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Gilead Sciences, Inc.
Hklaw· 16 Nov 2019

Rare HHS Patent Suit May Impact HIV Drug Pricing, Access

In a rare occurrence, the U.S. Department of Health and Human Services finds itself in the middle of a patent law suit against Gilead Sciences Inc. and this dispute could affect HIV drug pricing and accessibility.

  • Gilead Sciences, Inc.
  • Patent
  • Health and Human Services
  • Holland & Knight
  • Regulatory and Legal
  • Press Releases
  • Company Websites
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Baker Botts LLP
  • M&A Activities
  • Social Updates
  • Twitter
1 2 3 4 5